STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultMay 12, 2026, 04:13 PM

Hyperfine Q1 Revenue $3.90M, up 83%; Net Loss $8.62M

AI Summary

Hyperfine, Inc. reported strong first quarter 2026 financial results, with revenue increasing 83% year-over-year to $3.90 million and gross margin improving to 51%. The company also reduced its net loss to $8.62 million from $9.42 million in Q1 2025. Key business achievements include international regulatory approvals, progress in clinical studies, and the launch of the Swoop® system in India. Additionally, Hyperfine secured $15.0 million in debt financing, extending its cash runway into 2028.

Key Highlights

  • Revenue for Q1 2026 was $3.90 million, an 83% increase from Q1 2025.
  • Sold 10 commercial Swoop® systems in Q1 2026, up from 6 in Q1 2025.
  • Gross profit rose to $1.98 million (51% margin) in Q1 2026 from $0.88 million (41% margin) in Q1 2025.
  • Net loss decreased to $8.62 million ($0.09 per share) in Q1 2026 from $9.42 million ($0.12 per share) in Q1 2025.
  • Secured $15.0 million debt financing, extending cash runway into 2028.
  • Obtained CE Marking and UKCA approval for next-gen Swoop® system and Optive AI™ software.
  • Began launch activities in India with the first Swoop® system live at AIIMS, New Delhi.
  • Maintained full year 2026 revenue guidance of $20-$22 million and cash burn guidance of $26-$28 million.
HYPR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Hyperfine, Inc.

Price Impact